Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Stopped early · Phase 1

Conditions studied: Lymphoma, NHL, Non-Hodgkin Lymphoma

In brief

This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at the maximum dose identified in Part A. AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth

Key facts

Study ID

NCT00471367

Run by

AstraZeneca

People needed

44

Starts

2007-04-01

Expected to finish

2008-12-01

Last updated by the study team

2009-09-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Part A: Advanced solid tumors (including lymphoma without bone marrow involvement) for which standard treatment doesn't exist or is no longer effective.
• Part B: B-cell non-Hodgkin lymphoma that is not eligible for curative therapy or has relapsed.
• Relatively good overall health other than your cancer

You may not qualify if…

• Poor bone marrow function (not producing enough blood cells). Serious heart conditions. Poor liver or kidney function

Where it is running

• Research Site — New York, New York, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Greenville, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.